Inhibitor Therapeutics amends loan with Mayne Pharma: limit to $281K, maturity Dec 2022

Inhibitor Therapeutics, Inc.

Facility limit increased by $50,000 to $281,000; maturity extended to December 31, 2022.
Additional $50,000 available for drawdown from Feb 1 to Mar 31, 2022, in minimum $25,000 increments.
Original $231,000 fully drawn; proceeds used for working capital and deferred employee compensation.
Loan amendment with majority stockholder Mayne Pharma; rest of Loan Agreement unchanged.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.